Skip to main content
main-content

13.02.2019 | Original Article – Clinical Oncology | Ausgabe 4/2019

Journal of Cancer Research and Clinical Oncology 4/2019

Preoperative controlling nutritional status (CONUT) score as a novel immune-nutritional predictor of survival in non-metastatic clear cell renal cell carcinoma of ≤ 7 cm on preoperative imaging

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 4/2019
Autoren:
Ahmed Elghiaty, Jongchan Kim, Won Sik Jang, Jee Soo Park, Ji Eun Heo, Koon Ho Rha, Young Deuk Choi, Won Sik Ham
Wichtige Hinweise
Elghiaty A, Ham WS. Preoperative Controlling Nutritional Status (CONUT) Score as a Novel Immune-Nutritional Predictor of Survival Among Patients with Non-Metastatic Clear Cell Renal Cell Carcinoma of ≤ 7 cm on Preoperative Imaging [abstract]. In: Proceedings of the 38th annual congress of the Société Internationale d’Urologie; 2018 Oct 4–7; Seoul, South Korea.

Abstract

Purpose

This study aimed at investigating the prognostic value of Preoperative controlling nutritional status (CONUT) score in non-metastatic clear-cell renal cell carcinoma of ≤ 7 cm on preoperative imaging.

Methods

We retrospectively included 1046 among 1637 patients who underwent radical or partial nephrectomy for solid renal masses ≤ 7 cm (2005–2014) after excluding other pathology, conditions affecting CONUT score components, metastasis, regional lymphadenopathy, positive margin, and follow-up < 12 months. We defined high and low CONUT according to cut-off of (2). Multivariate Cox-regression analysis was used to predict factors affecting recurrence and survival. Kaplan–Meier curve was used for survival analysis.

Results

The median age and follow-up were 56 years and 63 months, respectively. 41 patients had recurrence (3.9%). CONUT was a predictor for recurrence-free, cancer-specific, and overall survival (HR 3.09, P = 0.003 and HR 4.66, P = 0.004 and HR 2.81, P = 0.003, respectively). A higher CONUT was significantly associated with worse 5 years recurrence-free (88.2% vs. 97.1%), cancer-specific (96.2% vs. 98.8%) and overall (90.9% vs. 96.5%) survival (log-rank, P = < 0.001, P = 0.006 and P = < 0.001, respectively).

Conclusions

The preoperative CONUT is an independent prognostic marker for survival after curative surgery for non-metastatic clear-cell renal cell carcinoma of ≤ 7 cm on preoperative imaging.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2019

Journal of Cancer Research and Clinical Oncology 4/2019 Zur Ausgabe

Original Article – Cancer Research

Expression of Syk and MAP4 proteins in ovarian cancer

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.